Vaishampayan, U. N., Muzaffar, J., Velcheti, V., Winer, I., Hoimes, C. J., Rosen, S. D., … Ernstoff, M. S. (2020). 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1). Annals of Oncology, 31, S708–S709. https://doi.org/10.1016/j.annonc.2020.08.1147

Vaishampayan, U. N., J. Muzaffar, V. Velcheti, I. Winer, C. J. Hoimes, S. D. Rosen, A. Spreafico, et al. “1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1).” Annals of Oncology 31 (September 2020): S708–9. https://doi.org/10.1016/j.annonc.2020.08.1147.

Vaishampayan UN, Muzaffar J, Velcheti V, Winer I, Hoimes CJ, Rosen SD, et al. 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1). Annals of Oncology. 2020 Sep;31:S708–9.

Vaishampayan, U. N., et al. “1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1).” Annals of Oncology, vol. 31, Elsevier BV, Sept. 2020, pp. S708–09. Crossref, doi:10.1016/j.annonc.2020.08.1147.

Vaishampayan UN, Muzaffar J, Velcheti V, Winer I, Hoimes CJ, Rosen SD, Spreafico A, McDermott DF, Chu QS-C, Dumas O, Gilbert L, Hirte H, Curtis KK, Du Y, Bidollari I, Sun L, Putiri E, Losey HC, Dezube B, Ernstoff MS. 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1). Annals of Oncology. Elsevier BV; 2020 Sep;31:S708–S709.